This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Biopharmaceutical School

Early Registration Savings Deadline Expires In:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Starting 14- 16 June 2022
3-day online training course

Olivier Negre
Co-Founder and Partner at Biotherapy Partners

Profile

Olivier developed his expertise in preclinical research and translational science through more than 20 years of experience in biotherapies. After working at Inserm on macrophages and at Bioprotein Technologies on vaccines, he joined bluebird bio (formerly Genetix Pharm) to develop gene therapies. He was R&D team leader for 10 years in Paris and Director preclinical & translational research for 5 years in Cambridge MA, USA. He contributed to the development of the first approved gene therapy for beta-thalassemia (Zynteglo), from preclinical studies to clinical trials and marketing authorization. In 2019, Olivier participated in founding Biotherapy Partners to foster drug developments in the field of cell and gene therapies. He is currently board member of the French Society and Gene and Cell Therapy, Co-President of the think tank Gene and Cell Therapy Institute in Paris, Head of R&D of a biotech company and Partner at Biotherapy Partners. 

Olivier is also instructor for Informa courses on cell and gene therapies. He contributed to several patents and scientific publications in the field of gene therapy (recently, Human Gene Therapy 2016, The New England Journal of Medicine 2017, The New England Journal of Medicine 2018, Science Translational 2019, Molecular Therapy Methods & Clin Dev 2020, BioDrugs 2020, The New England Journal of Medicine 2021). Olivier graduated from ENSTBB engineering school in Bordeaux and earned a PhD in cell and molecular biology from Paris 7 University.